UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

~~Securities~~Date ~~Exchange~~of ~~Act~~Report (Date of ~~1934~~earliest event reported): December 4, 2014

Date of Report (Date of earliest event reported): November 6, 2014

NIGHTINGALE, INC.

(Exact name of registrant as specified in its charter)

Delaware		87-044988-8
(State of incorporation)		(IRS Employer
		Identification No.)

Delaware

(State or other jurisdiction of incorporation)

33-23429-D

(Commission File Number)

87-044988-8

(IRS Employer ID No.)

33-23429-D

(Commission File Number)

1661 Lakeview Circle, Ogden, UT 84403

(Address of registrant’s principal executive office)

~~(801)~~Check ~~399~~the appropriate box below if the Form 8-~~3632~~K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (~~Registrant’s~~17 ~~telephone~~CFR ~~number~~230.425)

~~2232~~[ ~~Eastwood~~] ~~Boulevard,~~Soliciting ~~Ogden,~~material UTpursuant ~~84403~~to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

~~(Former~~[ ~~Name~~] orPre-commencement ~~Former~~communications ~~Address,~~pursuant ifto ~~Changed~~Rule ~~Since~~14d-2(b) ~~Last~~under ~~Report~~the Exchange Act (17 CFR 240.14d-2(b))

~~Check~~[ ~~the~~] ~~appropriate box below if the Form 8~~Pre-Kcommencement ~~filing~~communications ispursuant ~~intended~~ to ~~simultaneously~~Rule ~~satisfy~~13e-4(c) ~~the filing obligation of the registrant~~ under ~~any of~~ the ~~following~~Exchange ~~provisions~~Act (17 ~~see General~~CFR ~~Instructions A~~240.~~2. below~~13e-4(c):)

~~o Written~~Item ~~communications~~4.01 ~~pursuant~~Changes toin ~~Rule 425~~Registrant’s ~~under~~Certifying ~~the Securities Act (17 CFR 230~~Accountant.~~425)~~

~~o Soliciting~~(a) ~~material~~The ~~pursuant~~Registrant tois ~~Rule~~an inactive company and has filed no annual or periodic reports since the filing for the quarter ended June 30, 2002. On March 7, 2006, upon the authorization and approval of the Board of Directors of the Registrant, the Registrant engaged Spector & Wong (“S&W”) as its independent registered public accounting firm. No consultations occurred between the Registrant and S&W regarding either (i) ~~14a-12~~the ~~under~~application of accounting principles to a specific completed or contemplated transaction, the ~~Exchange~~type ~~Act~~of audit opinion that might be rendered on the Registrant’s financial statements, or other information provided that was an important factor considered by the Registrant in reaching a decision as to an accounting, auditing or financial reporting issue, or (17ii) any ~~CPR~~matter ~~240~~that was the subject of disagreement or a reportable event requiring disclosure.~~14a-12~~ During the time of Spector’s engagement as the Registrant’s independent registered public accounting firm, S&W did not issue any reports on the Registrant’s financial statements. As of the date of this report, to the best of the Registrant’s knowledge, S&W is no longer in business as an independent registered public accounting firm. Harold Spector, the principle partner of S&W died in 2011. During the brief period of time in which S&W was engaged (i) there were no disagreements between the Registrant and S&W on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure which, if not resolved to the satisfaction of S&W, would have caused S&W to make reference to the matter in a report on the Registrant’s financial statements; and (ii) there were no reportable events as the term described in Item 304(a)(1)(v) of Regulation S-K.

~~o Pre-commencement~~(b) ~~communications~~The ~~pursuant~~Registrant tohas ~~Rule 14d-2~~engaged Pritchett, Siler & Hardy, P.C. (b“PS&H”) ~~under~~ to serve as the ~~Exchange~~Registrant’s ~~Act~~independent ~~(17 CFR 240~~registered public accounting firm for the years ending December 31, 2012 and December 31, 2013.~~14d-2(b))~~ The Registrant did not consult with PS&H regarding the application of accounting principles to a specific completed or contemplated transaction, or the type of audit opinion that might be rendered on the Registrant’s financial statements for any of its prior fiscal years. The decision to engage PS&H was approved by the Registrant’s board of directors on December 4, 2014.

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Section 7 – Regulation FD

Item 7.01 Regulation FD.

The information set forth in Item 8.01 of this Current Report on Form 8-K is incorporated by reference into this Item 7.01.

Section 8 – Other Events

Item 8.01 Other Events.

On November 6, 2014, Nightingale, Inc. (the “Company”) entered into a non-binding letter of intent (“LOI”) with Cytograft Tissue Engineering, Inc. (“Cytograft”). The LOI provides for a potential merger transaction which, if completed, would result in the acquisition of Cytrograft by the Company. The proposed merger transaction is expected to be structured as a reverse triangular merger whereby a newly formed subsidiary of the Company (“Merger Sub”) will merge into Cytrograft and Cytrograft will become a wholly-owned subsidiary of the Company.

It is expected that the proposed merger transaction will be accounted for as a reverse merger with Cytrograft deemed to be the survivor for accounting purposes.

If the merger transaction is completed, of which there can be no assurance, the current officers and directors of the Company will resign and the current officers and directors of Cytograft or other designees, will be appointed in their place.

The proposed merger transaction is subject to various conditions including the completion of required financial statements, the raising of additional capital by the Company and other matters set forth in the LOI and the definitive Merger Agreement that will be prepared by the parties.

It is anticipated that immediately prior to the closing of the merger (if a closing occurs) the Company will have approximately 12,375,074 shares outstanding on a fully diluted basis. It is anticipated that as a result of the proposed merger, 42,225,000 shares of the Company’s common stock will be issued to the shareholders of Cytograft or reserved for issuance for holders of Cytrograft options and other convertible securities.

As stated above, there can be no assurance the parties will enter into a definitive Merger Agreement or that the proposed merger will be completed.

The Company has been inactive for most of the past ten years. Our business plan is to acquire one or more other companies that are either currently operating or that have business plans or intellectual properties that might result in long-term growth. We are required to file reports with the Securities and Exchange Commission under Section 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) but we are not a reporting company under Section 12(g) of the Exchange Act and we are not currently subject to the Proxy Rules. We are not current in our reports under the Exchange Act but are working on bringing our reports (Form 10-K’s and Form 10-Q’s) current as soon as practical.

There is no trading market in our common stock and there can be no assurance there will be a trading market in the future. If we are able to complete an acquisition, of which there can be no assurance, we anticipate that we will thereafter attempt to have a market in our common stock commenced.

Item 9.01 Financial Statements and Exhibits

~~(d) Exhibits~~None.

Exhibit No. Description

10.5 Letter of Intent dated November 6, 2014 between Nightingale, Inc. and Cytrograft Tissue Engineering, Inc.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the ~~registrant~~Registrant has duly caused this report to be signed on its behalf by the undersigned ~~thereunto~~hereunder duly authorized.

	Nightingale, Inc.
Date: November 12, 2014	By:	/s/ David Knudson
		Name:	David Knudson
		Title:	Secretary/Treasurer/Director

Dated: December 4, 2014

~~4834-7804-2656~~NIGHTINGALE, vINC. 1

By: /S/ David Knudson

Secretary/Treasurer

Filing Compare · NIGHTINGALE INC